A drug tipped for widespread use to prevent breast cancer in post-menopausal women also accelerates loss of bone density, thus potentially boosting the risk of fractures, a study published on Tuesday said.
A drug tipped for widespread use to prevent breast cancer in post-menopausal women also accelerates loss of bone density, thus potentially boosting the risk of fractures, a study published on Tuesday said.
Exemestane -- brand name Aromasin -- is part of a drug class called aromatase inhibitors, which lower levels of the oestrogen that some breast cancers need in order to grow.
This article is older than 60 days, which we reserve for our premium members only.You can subscribe to our premium member subscription, here.
About the author
- Writer: AFP News agency
- Position: Agence France-Presse
Latest stories in this category:
- UN Council condemns Syria government over massacre
- India rupee woes highlight economic drift
- Indian PM meets Myanmar president
- Cannes crowns 'Love' as Europe sweeps awards
- San Franciscans celebrate anniversary of Golden Gate Bridge
- Two monks 'self-immolate' in Tibet
- IMF chief riles Greeks as crisis election looms
- Nepal faces months of instability after talks fail
